Clinical Trials Browser

Has results × Waldenstrom Macroglobulinemia × zanubrutinib × Clear all

NCT03053440 2024-10-26

ASPEN

Phase 3 Completed

201 enrolled 19 charts 1 FDA

Waldenstrom Macroglobulinemia

NCT03332173 2024-10-26

Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)

Phase 2 Completed

44 enrolled 13 charts

Waldenstrom Macroglobulinemia